CAI Stock: Price, Earnings History and SEC Filings
Caris Life Sciences, Inc. (CAI) last traded at $34.33, down 5.01% on the latest session and up 12.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $-0.01, a beat of 100.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CAI earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.00 | $-0.01 | +100.00% |
| Mar 2026 | May 7, 2026 | $0.00 | $-0.02 | +100.00% |
| Dec 2025 | Feb 26, 2026 | $0.28 | $0.01 | +2700.00% |
| Sep 2025 | Nov 5, 2025 | $0.08 | $-0.08 | +200.00% |
CAI beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How CAI reacts to earnings
Across its last 6 earnings releases, CAI moved 12.7% on average the next session, in either direction. It rose after 3 of 6 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +21.58% |
| 2026-05-07 | After close | -18.60% |
| 2026-02-26 | After close | +4.68% |
| 2026-01-12 | Before open | -10.21% |
| 2025-11-05 | After close | -15.75% |
| 2025-08-12 | After close | +5.61% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CAI financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $812M | -$68M | $67M | -8.4% | $-3.22 |
| 2024 | $412M | -$282M | -$254M | -68.4% | $-10.66 |
| 2023 | $306M | -$341M | -$298M | -111.5% | $-13.24 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CAI
- 8-K · Sep 14, 2026Regulation FD disclosure
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 5, 2026Shareholder vote
- 10-Q · May 8, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 23, 2026
- 8-K · Apr 2, 2026Material agreement, Agreement terminated, New financial obligation
- 10-K · Mar 3, 2026
- 8-K · Feb 26, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
CAI insiders filed 11 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CAI news
- Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out forOct 28, 2026 · finance.yahoo.com
- Foundation Medicine Appoints Chadi Nabhan, M.D., MBA, as Chief Medical OfficerOct 22, 2026 · finance.yahoo.com
- Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer DetectionOct 19, 2026 · finance.yahoo.com
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc. (CAI) is a US-listed public company on Nasdaq. The SEC classifies its business as Services-medical Laboratories. It is incorporated in TX. Its fiscal year ends in December.